Breda, the Netherlands / Ghent, Belgium– arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has advanced ARGX-111, a best-in-class highly differentiated SIMPLE Antibody™ targeting c-MET driven malignancies, into the safety and efficacy expansion part of its Phase 1b study. The objective of the expansion cohort is to further characterize the safety of ARGX-111 in cancer patients with MET amplified tumors, and to evaluate efficacy signals in order to select the indications to be studied in Phase 2 clinical development.
We are pleased to have selected the dose of ARGX-111 to move forward into safety expansion cohort of the study. We based the selection on the results of the dose escalation portion of the study conducted in patients pre-screened for cancers with over-expression of c-Met, commented Alain Thibault, M.D., Chief Medical Officer at arGEN-X. Biological activity was illustrated especially in the context of MET amplification. We will recruit these types of patients for the upcoming expansion cohort and we expect to report interim data in the second half of 2016.
The full data from the dose escalation part of the Phase 1b study will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May – 2 June, in Chicago, IL, USA.
